J Pediatr Infect Dis
DOI: 10.1055/s-0044-1788048
1
Department of Pediatric Infections and Diseases, Ankara Bilkent City Hospital, Ankara, Türkiye
,
Selin Yildiz
1
Department of Pediatric Infections and Diseases, Ankara Bilkent City Hospital, Ankara, Türkiye
,
Avni Merter Keçeli
2
Department of Radiology, Ankara Bilkent City Hospital, Ankara, Türkiye
,
Saliha Kanik-Yüksek
1
Department of Pediatric Infections and Diseases, Ankara Bilkent City Hospital, Ankara, Türkiye
,
Zeliha Güzelküçük
3
Division of Pediatric Hematology/Oncology, Ankara Bilkent City Hospital, Ankara, Türkiye
,
Sema Turan Uzuntaş
4
Department of Medical Microbiology, Ankara Bilkent City Hospital, Ankara, Türkiye
,
Belgin Gülhan
1
Department of Pediatric Infections and Diseases, Ankara Bilkent City Hospital, Ankara, Türkiye
,
Elif Ayça Şahin
5
Department of Medical Microbiology, Gazi University Faculty of Medicine, Ankara, Türkiye
,
Aslı Nur Özkaya Parlakay
1
Department of Pediatric Infections and Diseases, Ankara Bilkent City Hospital, Ankara, Türkiye
,
Neşe Yarali
3
Division of Pediatric Hematology/Oncology, Ankara Bilkent City Hospital, Ankara, Türkiye
› Author Affiliations
Funding/Support The author(s) received no financial support for the research, authorship, and/or publication of this article.
› Further Information
Also available at
![SFX Search]()
Buy Article Permissions and Reprints
Abstract
The increasing incidence of invasive fungal infections, coupled with the growing population of immunocompromised patients, has led to an increased need for antifungal agents. The newest azole, isavuconazole, plays an important role in the treatment of invasive aspergillosis in adults due to its broad spectrum, tolerability, and no need for therapeutic drug monitoring. This agent, which has not yet been approved for use in children, has significant problems with drug supply in Türkiye. We present the treatment response to isavuconazole combination therapy used in salvage treatment in a patient with breakthrough invasive aspergillosis, who had treatment failure with different antifungal combination treatment options and surgical resection.
Keywords
aspergillosis -
isavuconazole -
salvage treatment -
pediatric
Role of Funder/Sponsor (if any)
None.
Publication History
Received: 11 January 2024
Accepted: 12 June 2024
Article published online:
08 July 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
References
1
Warris A,
Lehrnbecher T,
Roilides E,
Castagnola E,
Brüggemann RJM,
Groll AH.
ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children. Clin Microbiol Infect 2019; 25 (09) 1096-1113
2
Patterson TF,
Thompson III GR,
Denning DW.
et al.
Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63 (04) e1-e60
3
Donnelly JP,
Chen SC,
Kauffman CA.
et al.
Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis 2020; 71 (06) 1367-1376
4
Hsu AJ,
Tamma PD,
Fisher BT.
Challenges in the treatment of invasive aspergillosis in immunocompromised children. Antimicrob Agents Chemother 2022; 66 (07) e0215621
5
Ellsworth M,
Ostrosky-Zeichner L.
Isavuconazole: mechanism of action, clinical efficacy, and resistance. J Fungi (Basel) 2020; 6 (04) 324
6
Cojutti PG,
Carnelutti A,
Lazzarotto D.
et al.
Population pharmacokinetics and pharmacodynamic target attainment of isavuconazole against Aspergillus fumigatus and Aspergillus flavus in adult patients with invasive fungal diseases: should therapeutic drug monitoring for isavuconazole be considered as mandatory as for the other mold-active azoles?. Pharmaceutics 2021; 13 (12) 2099
7
Maertens JA,
Raad II,
Marr KA.
et al.
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 2016; 387 (10020): 760-769
8
Zurl C,
Waller M,
Schwameis F.
et al.
Isavuconazole treatment in a mixed patient cohort with invasive fungal infections: outcome, tolerability and clinical implications of isavuconazole plasma concentrations. J Fungi (Basel) 2020; 6 (02) 90
9
Decembrino N,
Perruccio K,
Zecca M.
et al.
A case series and literature review of isavuconazole use in pediatric patients with hemato-oncologic diseases and hematopoietic stem cell transplantation. Antimicrob Agents Chemother 2020; 64 (03) e01783-e19
10
Krishnan-Natesan S,
Chandrasekar PH,
Alangaden GJ,
Manavathu EK.
Molecular characterisation of cyp51A and cyp51B genes coding for P450 14alpha-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus. Int J Antimicrob Agents 2008; 32 (06) 519-524
11
Schmitt-Hoffmann A,
Roos B,
Maares J.
et al.
Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006; 50 (01) 286-293
留言 (0)